[go: up one dir, main page]

MX2016002881A - Moduladores del canal de sodio para el tratamiento de dolor y diabetes. - Google Patents

Moduladores del canal de sodio para el tratamiento de dolor y diabetes.

Info

Publication number
MX2016002881A
MX2016002881A MX2016002881A MX2016002881A MX2016002881A MX 2016002881 A MX2016002881 A MX 2016002881A MX 2016002881 A MX2016002881 A MX 2016002881A MX 2016002881 A MX2016002881 A MX 2016002881A MX 2016002881 A MX2016002881 A MX 2016002881A
Authority
MX
Mexico
Prior art keywords
diabetes
pain
treatment
sodium channel
compounds
Prior art date
Application number
MX2016002881A
Other languages
English (en)
Inventor
Olga Babich
Robert Z Luo
Yanlin Wang-Fischer
David J Palling
Srinivasan P Venkatachalan
Tina Garyantes
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of MX2016002881A publication Critical patent/MX2016002881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos moduladores de canal de sodio, en particular compuestos moduladores de NaV1.7 de la Fórmula I o compuestos de la Fórmula I': (ver Fórmula) Fórmula (I)/Fórmula (I'). En particular, se proporcionan procesos para la preparación de, intermedios usados en la preparación de, que comprenden composiciones farmacéuticas, y métodos terapéuticos que comprenden administrar estos compuestos. En particular, se proporcionan en la presente compuestos para el tratamiento de dolor y diabetes.
MX2016002881A 2013-09-10 2014-09-09 Moduladores del canal de sodio para el tratamiento de dolor y diabetes. MX2016002881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361876046P 2013-09-10 2013-09-10
PCT/US2014/054764 WO2015038533A2 (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Publications (1)

Publication Number Publication Date
MX2016002881A true MX2016002881A (es) 2016-04-21

Family

ID=52666496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002881A MX2016002881A (es) 2013-09-10 2014-09-09 Moduladores del canal de sodio para el tratamiento de dolor y diabetes.

Country Status (18)

Country Link
US (2) US20160221974A1 (es)
EP (1) EP3043787B1 (es)
JP (1) JP6445565B2 (es)
KR (1) KR20160054570A (es)
CN (1) CN105611923B (es)
AU (1) AU2014318979B2 (es)
BR (1) BR112016005271A2 (es)
CA (1) CA2922851C (es)
ES (1) ES2687598T3 (es)
IL (1) IL244506B (es)
MX (1) MX2016002881A (es)
MY (1) MY181928A (es)
PH (1) PH12016500296A1 (es)
RU (1) RU2016113156A (es)
SG (2) SG10201805552PA (es)
UA (1) UA120353C2 (es)
WO (1) WO2015038533A2 (es)
ZA (1) ZA201702410B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022096A8 (pt) * 2013-03-15 2019-11-26 Chromocell Corp compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
MX2016002881A (es) 2013-09-10 2016-04-21 Chromocell Corp Moduladores del canal de sodio para el tratamiento de dolor y diabetes.
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
SG11201804936UA (en) 2015-12-18 2018-07-30 Merck Sharp & Dohme Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
KR102366077B1 (ko) 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN105924670A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种电力电缆用耐磨剂
CN105924843A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆
CN106084535A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆的制备方法
KR20190086772A (ko) 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN106892845B (zh) * 2017-02-28 2018-10-30 四川同晟生物医药有限公司 一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
AU2019285184B2 (en) 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2019331005B2 (en) 2018-08-31 2024-03-28 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DE50212652D1 (de) * 2001-03-14 2008-09-25 Gruenenthal Gmbh Substituierte Thiazolopyrimidine als Analgetika
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
WO2006011050A2 (en) * 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
JP5473334B2 (ja) * 2005-12-23 2014-04-16 ジーランド ファーマ アクティーゼルスカブ 修飾リジン模倣化合物
MX2009008338A (es) * 2007-02-05 2009-08-12 Xenon Pharmaceuticals Inc Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
ES2523196T3 (es) 2007-07-13 2014-11-21 Icagen, Inc. Inhibidores de los canales de sodio
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
CN105130957A (zh) 2009-05-29 2015-12-09 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
JP5830534B2 (ja) * 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
SG191993A1 (en) 2011-01-18 2013-08-30 Amgen Inc Nav1.7 knockout mice and uses thereof
TWI549944B (zh) * 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013025883A1 (en) 2011-08-17 2013-02-21 Amgen Inc. Heteroaryl sodium channel inhibitors
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
BR112015022096A8 (pt) * 2013-03-15 2019-11-26 Chromocell Corp compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
HRP20201701T8 (hr) 2013-09-09 2022-01-07 Peloton Therapeutics, Inc. Aril eteri i njihove uporabe
MX2016002881A (es) 2013-09-10 2016-04-21 Chromocell Corp Moduladores del canal de sodio para el tratamiento de dolor y diabetes.
WO2016040315A1 (en) 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
IL244506A0 (en) 2016-04-21
SG10201805552PA (en) 2018-08-30
EP3043787A2 (en) 2016-07-20
EP3043787B1 (en) 2018-09-05
CN105611923A (zh) 2016-05-25
JP2016532716A (ja) 2016-10-20
ES2687598T3 (es) 2018-10-26
AU2014318979A1 (en) 2016-03-03
US20160221974A1 (en) 2016-08-04
UA120353C2 (uk) 2019-11-25
RU2016113156A (ru) 2017-10-16
CA2922851C (en) 2023-03-14
AU2014318979B2 (en) 2019-03-28
WO2015038533A2 (en) 2015-03-19
RU2016113156A3 (es) 2018-07-02
WO2015038533A3 (en) 2015-10-29
ZA201702410B (en) 2019-06-26
IL244506B (en) 2020-02-27
PH12016500296A1 (en) 2016-05-16
CN105611923B (zh) 2019-08-23
SG11201601367QA (en) 2016-03-30
US9458118B2 (en) 2016-10-04
EP3043787A4 (en) 2017-02-01
JP6445565B2 (ja) 2018-12-26
MY181928A (en) 2021-01-14
US20160130239A1 (en) 2016-05-12
KR20160054570A (ko) 2016-05-16
CA2922851A1 (en) 2015-03-19
BR112016005271A2 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
PH12015500825B1 (en) Substituted benzene compounds
PH12014501560A1 (en) Carbamate compounds and of making and using same
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
MX2013011922A (es) Compuestos de benceno substituido.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
PH12015501609A1 (en) Phenicol antibacterials
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX2016001357A (es) Compuestos de ciclobutilo 1,2-disustituidos.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов

Legal Events

Date Code Title Description
FG Grant or registration